Sermorelin
10MGGHRH (1-29) amide, 29 residues.
6 peer-reviewed citations for this compound
Read the sourcesVolume tiers count vials of this compound at this strength. Mixing different compounds does not combine toward a tier.
- ≥99% purity specification
- Secure checkout
- Ships in 1 business day
- Research use only
Released against a ≥99% HPLC purity specification and supplied as a sealed laboratory reagent for in vitro research use only.
- Type
- GHRH (1-29) amide
- CAS number
- 86168-78-7
- Molecular formula
- C149H246N44O42S
- Molecular weight
- 3357.9 g/mol
- Amino acids
- 29
- Form
- Lyophilized powder
- Vial strength
- 10MG
- Purity specification
- ≥99% by HPLC
Identifiers are published properties of the molecule. Values we cannot confirm are omitted rather than estimated.
Dispatch
Ships within 1 business day of order confirmation, from the US. Vials ship lyophilized at ambient temperature; move them to the storage condition below on arrival.
Lyophilized
Store at -20°C, protected from light. Stable 24+ months sealed.
Reconstituted
Store at 2-8°C. Use within approximately 30 days.
How Sermorelin is described to act.
Sermorelin is GHRH(1-29)-NH2, described as the shortest synthetic fragment of human growth hormone-releasing hormone retaining full biological activity of the parent hormone. It binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and release of endogenous growth hormone, so its output depends on an intact pituitary somatotroph population. In normal men, intravenous bolus dosing produced integrated plasma GH responses of molar potency similar to GHRH(1-40) and GHRH(1-44), while a D-Ala2 analog was approximately twice as potent. Reported endocrine selectivity was high in that study: no changes were observed in prolactin, TSH, LH, FSH, ACTH, insulin, glucagon, glucose, cortisol, or free thyroid hormones.
Mechanistic descriptions summarize published in vitro and animal work. They are not a representation of efficacy or safety in any subject, and no administration guidance is given or implied.
Because release is pituitary-dependent, the literature characterizes sermorelin substantially as a diagnostic provocative agent. Review data in children report that fewer false-positive GH responses occur after intravenous sermorelin than after other provocative tests, while noting that a normal response cannot exclude growth hormone deficiency of hypothalamic origin. A randomized 6-month pediatric study assigned 43 prepubertal children to low-dose GHRH(1-29)-NH2, high-dose GHRH(1-29)-NH2, or growth hormone, with anthropometry, bone age, GHRH provocative testing, and IGF-I as endpoints. In older adults, a 6-week study of nightly subcutaneous GHRH(1-29) in 11 healthy men aged 64-76 measured overnight GH secretion at 20-minute intervals, IGF-I, IGFBP-3, GHBP, muscle strength and histology, forearm muscle bioenergetics by 31P-NMR spectroscopy, and body composition by DEXA. Twice-daily GHRH(1-29) has separately been studied in older men with circulating GH and IGF-I concentrations as endpoints.
Sources & references
Cited literature is provided for scientific reference only and does not constitute a representation of efficacy or safety in any subject. All research findings presented are sourced from peer-reviewed journals and are provided for educational reference only.
- 01Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Walker RF · Clin Interv Aging, 2006
- 02
- 03
- 04Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone
Neyzi O, et al. · Acta Paediatr Suppl, 1993
- 05Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men
Corpas E, et al. · J Clin Endocrinol Metab, 1992
- 06
Every entry links to its record at the publisher or on PubMed. Titles are reproduced exactly as published.
Further searches
Live database searches for Sermorelin, run against the current index and retrieved independently of this site.
Bench handling, not a dosing guide.
Intended use
Supplied exclusively as a research reagent for in vitro and laboratory use by qualified researchers. Not a drug, dietary supplement, cosmetic or medical device, and not for human or veterinary use. No dosing, route or administration guidance is provided for any compound in this catalog.
Personal protection
Handle in a controlled laboratory environment with gloves and eye protection. Avoid generating or inhaling airborne particulate when opening a vial, and do not handle the material outside a designated work area.
Opening and reconstitution
Lyophilized peptides are hygroscopic. Let the sealed vial equilibrate to room temperature before opening so atmospheric moisture does not condense onto the powder. Reconstitute by directing diluent down the vial wall and swirling until dissolved — do not shake, which shears and foams the peptide.
Stability and aliquoting
Store at -20°C, protected from light. Stable 24+ months sealed. Store at 2-8°C. Use within approximately 30 days. Aliquot reconstituted material and minimize repeated freeze-thaw cycles.
Waste disposal
Dispose of unused material, reconstituted solutions and sharps through your institution's chemical and biological waste stream, in accordance with local regulations. Do not dispose of research material in domestic waste or to drain.
Others in secretagogue research
CJC-1295 (no DAC)
Modified GRF (1-29) secretagogue analog.
CJC (no DAC) / Ipamorelin
Mod GRF (1-29) and ipamorelin blend.
IGF-1 LR3
83-residue recombinant IGF-1 analog.
Ipamorelin
Selective pentapeptide growth-hormone secretagogue.
Important research notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
This material is supplied exclusively as a research reagent for in vitro and laboratory use by qualified researchers. It is not a drug, dietary supplement, cosmetic, or medical device, is not intended for human or veterinary use, and is not intended to diagnose, treat, cure, or prevent any disease. No dosing, administration, therapeutic, or benefit claims are made or implied. Cited literature is provided for scientific reference only and does not constitute a representation of efficacy or safety in any subject.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.